Standard and Hypofractionated Dose Escalation to Intraprostatic Tumour Nodules in Localized Prostate Cancer

This journal activity, Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: 5-Year Efficacy and Toxicity in the DELINEATE Trial, provides practitioners with information on the side effects and efficacy associated with the use of a focal boost in patients with intermediate or high-risk prostate cancer receiving treatment with hypofractionated radiotherapy.

Please visit https://www.redjournal.org/article/S0360-3016(22)03349-1/fulltext to read the related journal article online. 

This activity is available from January 6, 2023, through 11:59 p.m. Eastern time on January 5, 2025.

Target Audience

This course is designed to meet the interest of radiation oncologists and radiation oncology residents.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Analyze bowel and bladder side effects associated with use of a focal boost in patients receiving hypofractionated radiotherapy.
  • Compare the side effects associated with use of a focal boost in patients receiving hypofractionated radiotherapy compared with use of a focal boost in patients receiving conventional radiotherapy.  
     

 

 

 

 

 

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
01/06/2023
Course expires: 
01/05/2025
Cost:
$49.00
Rating: 
0

Sue Yom, MD, PhD, FASTRO is employed by the University of California and receives compensation from Bristol-Myers Squibb, NRG Oncology, EMD Serono.

The person(s) above served as the developer(s) of this activity. Additionally, Education Committee had control over the content of this activity.

All relevant relationships have been mitigated.

 

Disclosure link: 
ASTRO Education Committee

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$49.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.

  • Nonmember: $49
  • Member: $0


Policies:

No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until January 5, 2025, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.

 

 

 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Ingternet Explorer or Safari.